Skip to main content

Home

Quarterly Results, Annual Reports and Proxy

Overview
Press Releases
Events
Stock Information
- NASDAQ: CGEN
- TASE: CGEN.TA
Analyst Coverage
Financials
- Quarterly Results, Annual Reports and Proxy
- SEC Filings
Media
Governance
Investor Contacts
Investor FAQs
Corporate Presentation

Quarterly Results Archive

Select Year

Selecting a year value will change the accordion list

Select Year:

Proxy Statement

Proxy Statement

2025 Proxy Statement

Headquarters

Compugen Ltd.

Azrieli Center
26 Harokmim St., Bldg D
Holon 5885849, Israel

Investor Contact

Yvonne Naughton, PhD, CIR
Vice President and Head of Investor Relations and Corporate Communications
Cambridge, United Kingdom
Telephone: +16282410071
Email: ir@cgen.com

Investor Email Alerts

Personal Information.

Your Email *Required

Mailing Lists *

Press Releases
End of Day Stock Quote
Events

About

About Compugen opens in new window
Leadership opens in new window
Board of Directors opens in new window
Scientific and Strategic Advisory Board opens in new window
Contact Us opens in new window

Unigen™

Overview opens in new window

Pipeline

Overview opens in new window
COM701/COM902/Pembrolizumab Triple Combination opens in new window
COM902/high affinity Fc reduced anti-TIGIT antibody opens in new window
GS-0321 opens in new window
Discovery Programs opens in new window
RILVEGOSTOMIG/Fc reduced anti-PD1/TIGIT bispecific antibody opens in new window

Clinical Trials

MAIA-ovarian opens in new window
COM701/COM902/Pembrolizumab Triple Combination opens in new window
Rilvegostomig opens in new window
GS-0321 (previously COM503) opens in new window

Privacy Policy opens in new window
Terms of Use opens in new window
Accessibility Statement opens in new window
Site Map opens in new window

© 2026 Compugen Ltd - All rights reserved

Powered By Q4 Inc. 5.173.0.1 (opens in new window)